To discern the cellular subsets susceptible to IL-6R blockade that could compromise the responsiveness to immune checkpoint inhibition and radiotherapy, we assessed the expression of IL6R in human pancreatic tumors. The gene discussed is IL6R; the disease is pancreatic neoplasm.